Cargando…

PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3’-UTR structural variations

Immune evasion mediated by PD-L1 plays an important role in the development of B-cell malignancies. However, PD-L1 expression is infrequently observed in tumor cells of extranodal diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Other than copy number alterations, PD-L1 is aberra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahara, Taishi, Ishikawa, Eri, Suzuki, Yuka, Kogure, Yasunori, Sato, Akira, Kataoka, Keisuke, Nakamura, Shigeo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JSLRT 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353849/ https://www.ncbi.nlm.nih.gov/pubmed/35474033 http://dx.doi.org/10.3960/jslrt.21028

Ejemplares similares

PD‐L1 expression on tumor or stromal cells of nodal cytotoxic T‐cell lymphoma: A clinicopathological study of 50 cases
por: Yamashita, Daisuke, et al.
Publicado: (2020)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
por: Suzuki, Yuka, et al.
Publicado: (2020)

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

Diagnostic approach for classic Hodgkin lymphoma in small samples with an emphasis on PD-L1 expression and EBV harboring in tumor cells: a brief review from morphology to biology
por: Takahara, Taishi, et al.
Publicado: (2023)

Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases
por: Takahashi, Emiko, et al.
Publicado: (2023)

Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1
por: Feng, Yu, et al.
Publicado: (2020)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
por: Hirose, Takayuki, et al.
Publicado: (2017)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma
por: Gao, Li-Min, et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020)

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
por: Garcia-Lacarte, Marcos, et al.
Publicado: (2021)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cdl1k3tnojk5e9dsa0b5eseist